Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Neuland Laboratories has informed that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, May 15, 2025, to Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2025; and Recommend final dividend, if any, for the financial year 2024-25. In continuation to letter dated March 25, 2025, pursuant to the Company's Insider Trading Code, the trading window for dealing in the equity shares of the Company shall continue to remain closed from April 1, 2025 till 48 hours after the declaration of audited financial results of the Company for the quarter and financial year ended March 31, 2025 and final dividend, if any, for the financial year 2024-25 to the stock exchanges.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.25 |
| Dr. Reddys Lab | 1214.95 |
| Cipla | 1227.85 |
| Zydus Lifesciences | 928.65 |
| Lupin | 2297.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: